Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells

Published On: November 04, 2015 | Pages: 009 - 017

Author(s): Richard J Rickles, Junji Matsui, Ping Zhu, Yasuhiro Funahashi, Jill M Grenier, Janine Steiger, Nanding Zhao, Bruce A Littlefield, Kenichi Nomoto and Toshimitsu Uenaka*,

Eribulin sensitivity was examined in a panel of twenty-five human cancer cell lines representing a variety of tumor types, with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in sensitivity to eribulin at clinically relevant concentrations. To identify combination drugs capable of increasing anticancer effects in patients already ...
Financial Crisis and Health

Published On: November 06, 2015 | Pages: 018 - 019

Author(s): Maria Saridi*

The financial crisis has a dramatic impact on social life, since reduced or even non-existent incomes affect people’s well-being and push big parts of the population to poverty. The individuals’ financial status affects health indicators such as life expectancy, morbidity, mortality and healthcare service accessibility [11. WHO (2009) Impact of the financial crisis on ...]

Abstract View | Full Article View | DOI: 10.17352/gjct.000005

An Overview of Thyroid Cancer Genetics and Inheritance

Published On: March 30, 2015 | Pages: 007 - 008

Author(s): Diana Navas-Carrillo and Esteban Orenes-Pinero*

Thyroid cancer (TC) is the most common endocrine malignancy and its incidence has been increasing sharply since the mid-1990s [1]. TC is a general term that comprises two main groups of neoplasias, depending on the cell type affected by the malignant transformation. 1) Carcinomas originating from the follicular epithelium, referred to as nonmedullary thyroid cancer (NM ...]

Abstract View | Full Article View | DOI: 10.17352/gjct.000003

Novel Strategies to Improve Rituximab Efficacy in Non-Hodgkin's Lymphomas

Published On: March 10, 2015 | Pages: 005 - 006

Author(s): Massimo Bortolotti and Letizia Polito*

Non-Hodgkin’s lymphomas (NHLs) are the second fastest growing cancer in terms of incidence and deaths in the United States and Europe. NHLs are a heterogeneous cancer group including several haematological neoplasias with different degree of aggressiveness. In spite of the progresses, conventional therapies do not ensure long-term survival [1]. The NHL patients, who h ...